Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

0 avis

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

Archive ouverte

Edité par CCSD ; Springer Verlag -

International audience. Clinical response to bevacizumab varies between patients treated for metastatic colorectal cancer (mCRC). The aim of this study was to quantify individual factors affecting bevacizumab pharmacokinetic variability and assess the relationship between bevacizumab concentrations and clinical outcomes.

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients

Archive ouverte | Lobet, Sarah | CCSD

International audience. Aims The exposure‐response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time‐dependent target engagement and recursive relationships b...

Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases

Archive ouverte | Tranquart, François | CCSD

IF 3.892. International audience. Purpose To evaluate changes in tumor vascularization parameters based on contrast-enhanced ultrasound (CEUS) quantification criteria of at least one visible liver metastasis as an e...

Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer

Archive ouverte | Chautard, Romain | CCSD

International audience. Background and aims: Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have ...

Chargement des enrichissements...